Page last updated: 2024-12-07
siagoside
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
siagoside: internal ester of GM1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
alpha-Neu5Ac-(2->3)-[beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-N-stearoylsphingosine 1(II'),2(II) lactone : A sialotetraosylceramide consisting of the disialoganglioside GM1 with a lactone ring formed between C-1 of the NeuNac residue and C-2 of the galactose residue proximal to the ceramide moiety. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 91617599 |
CHEMBL ID | 3989560 |
CHEBI ID | 141641 |
MeSH ID | M0146204 |
Synonyms (22)
Synonym |
---|
CHEBI:141641 |
alpha-neu5ac-(2->3)-[beta-d-gal-(1->3)-beta-d-galnac-(1->4)]-beta-d-gal-(1->4)-beta-d-glc-(1<->1')-n-stearoylsphingosine 1(ii'),2(ii) lactone |
ganglioside gm1 1(ii'),2(ii) lactone |
gm1 lactone |
beta-d-gal-(1,3)-beta-d-galnac-(1-4)-[alpha-neu5ac-(2-3,1-2)]-beta-d-gal-(1-4)-beta-d-glc-(1-1)-cer |
ganglioside gm1 lactone |
beta-d-galp-(1->3)-beta-d-galpnac-(1->4)-[alpha-neup5ac-(2->3,1->2)]-beta-d-galp-(1->4)-beta-d-glc-(1-<->1)-n-stearoylsphingosine |
(2s,3r,4e)-3-hydroxy-2-(octadecanoylamino)octadec-4-en-1-yl 5-acetamido-3,5-dideoxy-d-glycero-alpha-d-galacto-non-2-ulopyranonosyl-(2->3)-[beta-d-galactopyranosyl-(1->3)-2-acetamido-2-deoxy-beta-d-galactopyranosyl-(1->4)]-beta-d-galactopyranosyl-(1->4)-be |
siagoside [inn] |
octadecanamide, n-((1s,3r,3e)-1-(((o-(n-acetyl-alpha-neuraminosyl)-(2-3)-o-(o-beta-d-galactopyranosyl-(1-3)-2-(acetylamino)-2-deoxy-beta-d-galactopyranosyl-(1-4)-o-beta-d-galactopyranosyl-(1-4)-beta-d-glucopyranosyl)oxy)methyl)-2-hydroxy-3-heptadecenyl)-, |
6qfj0908r2 , |
ganglioside gm1, intramol. 1(b1),2(b)-ester |
100345-64-0 |
siagoside |
siagosido |
unii-6qfj0908r2 |
n-(ll(sup 3)-n-acetylneuraminosylgangliotetraosyl)ceramide, intramolecular ester |
siagosidum |
siagosidum [inn-latin] |
siagosido [inn-spanish] |
CHEMBL3989560 |
Q27265329 |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" There was a significant effect in all patients in the primary outcome variable (the percentage of marked recovery) at week 8, the end of the dosing period." | ( The Sygen multicenter acute spinal cord injury study. Coleman, WP; Geisler, FH; Grieco, G; Poonian, D, 2001) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
Class | Description |
---|---|
sialotetraosylceramide | A ganglioside in which the oligosaccharide portion is composed of an tetrasaccharide, to which one or more sialic acid residues are attached. |
lactone | Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (15)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (20.00) | 18.7374 |
1990's | 8 (53.33) | 18.2507 |
2000's | 4 (26.67) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (6.25%) | 5.53% |
Reviews | 1 (6.25%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |